Table 3 Baseline characteristics of the TNBC age subgroups (<50, 50–64, and ≥65)
TNBC | <50 (283) | 50-64 (274) | ≥65 (287) | |
|---|---|---|---|---|
Mean | Mean | Mean | p-value | |
Age (mean, range) | 41.9 (27; 50) | 57.7 (50; 65) | 73.3 (65; 97) | <0.001 |
Postmenopausal | 9.9% | 88.3% | 100.0% | <0.001 |
T 1 | 58% | 47.8% | 39.7% | <0.001 |
T 2 | 34.6% | 42% | 47.4% | |
T 3 | 6.4% | 6.2% | 5.2% | |
T 4 | 1.1% | 4% | 7.7% | |
Node negative | 66.8% | 61.7% | 59.2% | 0.165 |
1-3 | 19.8% | 21.2% | 19.2% | |
>3 | 13.4% | 17.2% | 21.6% | |
G 1 | 0.7% | 2.2% | 1.4% | 0.012 |
G 2 | 18.7% | 29.2% | 28.2% | |
G 3 | 80.6% | 68.6% | 70.4% | |
ASA Score ≥3 | 5.5% | 13.1% | 37.8% | <0.001 |
NYHA Class ≥ III | 0.9% | 4.1% | 8.3% | 0.030 |
Myocardial infarction, stroke, or TIA | 0.5% | 2.7% | 7.1% | <0.001 |
Endocrine therapy | 5.7% | 6.6% | 4.5% | 0.573 |
Chemotherapy | 90.8% | 86.5% | 54.7% | <0.001 |
Mastectomy | 18.7% | 21.5% | 39.4% | <0.001 |
Radiotherapy | 86.2% | 88.0% | 67.2% | <0.001 |